DRTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alpha Tau Medical Ltd (DRTS) is not a strong buy for a beginner, long-term investor at this time. While the company has promising technology and positive news catalysts, its financial performance remains weak, with no revenue and significant net losses. Additionally, the technical indicators and options data do not suggest a strong entry point currently. The stock may be worth monitoring for future developments, but it does not meet the criteria for a strong buy today.
The MACD histogram is negative (-0.0285) and contracting, indicating weak momentum. RSI is neutral at 47.148, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level (6.936), with resistance at 7.375 and support at 6.497. Overall, the technical indicators do not suggest a strong buy signal.
Japan's approval of Alpha DaRT for head and neck cancer, which validates the technology and opens partnership opportunities.
Breakthrough Device Designation from the U.S. FDA for recurrent cutaneous squamous cell carcinoma.
Positive sentiment on Stocktwits and a year-to-date gain of 38%.
Piper Sandler downgraded the stock to Neutral, citing valuation concerns and the lack of near-term revenue realization.
The company's path to full commercialization of its technology is still 2-3 years away.
Weak financial performance with no revenue and significant net losses.
In 2025/Q4, the company reported no revenue growth (0% YoY), a net loss of $12.14M (improved by 28.07% YoY), and an EPS of -0.14. Gross margin remains at 0%. The financials indicate no revenue generation and ongoing losses, which are concerning for a long-term investment.
Analysts are mixed. Citi and H.C. Wainwright maintain Buy ratings with price targets of $9 and $12, respectively, citing underappreciation of the company's platform and Japan approval as positives. However, Piper Sandler downgraded the stock to Neutral with a $5 price target, citing valuation concerns and the lack of near-term revenue realization.
